WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) Monday
said that its preliminary revenue for the fourth quarter and the full year
increased by 113 percent and 56 percent respectively, year on year.

Preliminary quarterly revenue is reported at around $58.4 million and yearly
revenue at around $200.5 million.

On average, 15 analysts polled by Thomson Reuters had expected revenue of $55.82
million for the quarter and $197.97 million for the year. Analysts' estimates
typically exclude special items.

The company continues to target a compound annual revenue growth of 40 percent
to 50 percent through 2026 based on a 2022 revenue base of $128.3 million,
representing a 2026 revenue target of over $500 million.

The fourth quarter results are expected to be reported in February along with
the guidance for fiscal 2024.

In pre-market activity, PacBio shares are trading at $8.84, down 5.96% on the
Nasdaq.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX